Comparison Of Two Tablet Formulations Of SB-568859

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

SB-568859 is a medication that is being developed for the treatment of atherosclerosis (hardening of the arteries). The purpose of this study is to see if there is a difference in how the human body takes up the study drug depending on how the study drug is made. This study will compare SB-568859 tablets that are made in 2 different ways. This is not a treatment study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Healthy men and sterile women between 18 and 50 years old

• Body weight greater than 50 pounds and a body mass index between 19 and 31

• Normal electrocardiogram

Exclusion criteria:

• No history of asthma or severe allergic reactions

• No history of or current drug use

• No Hepatitis or HIV/AIDS

• No excessive alcohol use

• No smoking or tobacco use

• No use of prescription drugs, over-the-counter drugs or vitamins within 7 days

• No use of herbal supplements within 14 days

• No treatment with an investigational drug within 30 days.

• No treatment with 4 or more investigational drugs in the last 12 months

• No grapefruit or grapefruit juice in the last 7 days

• No donation of blood in the last 8 weeks

• No history of allergy to heparin

• No history of liver or gall bladder disease

• Unwillingness to use contraception